CN Patent

CN109923106B — toll样受体调节剂化合物

Assigned to Gilead Sciences Inc · Expires 2022-09-13 · 4y expired

What this patent protects

本申请涉及Toll样受体调节剂(例如TLR8)式I化合物和含有它们的药物组合物。该化合物可用于治疗过度增殖性疾病，例如癌症或病毒感染如乙型肝炎和HIV。

USPTO Abstract

本申请涉及Toll样受体调节剂(例如TLR8)式I化合物和含有它们的药物组合物。该化合物可用于治疗过度增殖性疾病，例如癌症或病毒感染如乙型肝炎和HIV。

Drugs covered by this patent

Patent Metadata

Patent number: CN109923106B
Jurisdiction: CN
Classification: —
Expires: 2022-09-13
Drug substance claim: No
Drug product claim: No
Assignee: Gilead Sciences Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.